The efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer
A meta-analysis
Lin-guang-jin Wu, BMa, Dan-ni Zhou, BMb, Ting Wang, BMa, Jun-zhi Ma, BAe, Hua Sui, MDd, Wan-li Deng, MDa,∗

Abstract
Background: Immune checkpoint inhibitor therapy for non-small cell lung cancer is widely used in clinical practice. However, there has not been a systematic statistical proof of the efficacy of PD-1 inhibitors in patients with advanced cancer. This meta-analysis aims to evaluate its efficacy and related influencing factors, so as to provide a basis for clinical diagnosis and treatment.

Objective: To assess the effectiveness and safety of programmed death-1 (PD-1)/PD ligand 1 (PD-L1) inhibitors versus chemotherapy as second-line or late-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) via a systematic review of published randomized controlled trials (RCTs).

Methods: Studies were identified through PubMed, EMBASE, and Cochrane Library electronic databases. RevMan 5.3.5 was used to analyze the data extracted from all eligible studies.

Results: All 4122 eligible patients from 8 RCTs were included in this study. The meta-analysis showed that PD-1/PD-L1 inhibitors could significantly improve overall survival (hazards ratio [HR] 0.71, 95% confidence interval [CI] 0.66–0.77, P < .001), progression-free survival (HR 0.88, 95%CI 0.81–0.94, P = .01), and objective response rate (HR 2.03, 95%CI 1.66–2.49, P < .001) compared with chemotherapy drugs. The incidence of side effects of any grade (HR 0.34, 95%CI 0.29–0.39, P < .001) or grades 3 to 5 (HR 0.15, 95%CI 0.10–0.23, P < .001) consistently showed that PD-1/PD-L1 inhibitors were safer than chemotherapy. Furthermore, subgroup analysis based on tumor proportion score or pathology classification revealed that PD-1/PD-L1 inhibitors significantly improved overall survival compared with chemotherapy.

Conclusion: As a second-line or late-line treatment, PD-1/PD-L1 inhibitors are safer and more effective than chemotherapy in patients with advanced NSCLC.

Abbreviations: CI = confidence interval, HR = hazards ratio, NSCLC = non-small-cell lung cancer, ORR = objective response rate, OS = overall survival, PD-1 = programmed death 1, PD-L1 = programmed death ligand 1, PFS = progression-free survival, RCTs = randomized controlled trials, TPS = tumor proportion score.

Keywords: advanced NSCLC, chemotherapy, meta-analysis, PD-1/PD-L1 inhibitors, squamous, tumor proportion score.
1. Introduction

Lung cancer is one of the most common malignancies globally.\(^{[1]}\) Non-small-cell lung cancer (NSCLC) accounts for more than 80% of cancer cases, and the 5-year survival rate of patients with this cancer is approximately 16%.\(^{[2]}\) Most (65%) patients with NSCLC are diagnosed when the cancer is locally advanced (IIB) or metastatic (IV), and the 5-year survival rates for patients with these NSCLC types are 5% and 1%, respectively. Patients receiving palliative care suffer from a high symptom burden and from side effects of toxic treatments.\(^{[3]}\)

Immune checkpoint inhibitors are a new standard of treatment for patients with advanced NSCLC without abnormalities in epidermal growth factor receptor tyrosine kinase or anaplastic lymphoma kinase genes. In the case of NSCLC, programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1), which is expressed on activated T cells and pro-B cells, to avoid killing by immune cells and thus prevents immune surveillance. Although the introduction of PD-1 or PD-L1 inhibitors into clinical practice has revolutionized cancer treatment, consistent response and beneficial long-term results have only been observed in few patients.\(^{[4]}\) Furthermore, several treatment-related side effects have been noted following first-line therapy with PD-L1 inhibitors in combination with chemotherapy\(^{[5]}\) or PD-L1 inhibitors alone.\(^{[6]}\)

With the current increase of clinical trials in this area, most of them have not been included in a systematic evaluation to accurately compare the safety and efficacy of PD-L1 inhibitors as a second- or later-line therapy with those of chemotherapy for advanced NSCLC. Therefore, the aim of this research was to investigate and analyze the latest randomized control trial (RCT) evidence regarding the efficacy and safety of PD-L1 inhibitors alone with those of chemotherapy for treating advanced NSCLC. We also investigated whether tumor pathology or PD-L1 expression determined using tumor proportion score (TPS) can affect the treatment selection for patients.

2. Methods

This study was based on the recommendations of the Cochrane Handbook for systematic reviews of interventions, and was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement guidelines.\(^{[7]}\)

The registered study protocol is available on PROSPERO database (identification number: CRD42020158037).

2.1. Database and search strategy

This meta-analysis was performed by searching the PubMed, EMBASE, and Cochrane Library databases from inception to March 2020 with no language restrictions (for details on the search strategy in EMBASE, refer to Supplemental S1, http://links.lww.com/MD/F948). The primary keywords used were as follows: “Pulmonary Neoplasms,” “Carcinoma, Non-Small-Cell Lung,” “Antineoplastic Agents,” “Antibodies, Monoclonal, Humanized,” “Advanced,” “Metastasis,” “pembrolizumab,” “nivolumab,” “durvalumab,” “atezolizumab,” “avelumab,” “Docetaxel Trihydrate,” and “randomized controlled trial.”

After the comprehensive search, the shortlisted studies were screened. Three authors independently reviewed and cross-checked the quality of the included articles and evaluated them.

2.2. Selection criteria

The pre-specified criteria for RCT inclusion in the study were as follows:

1) Population: Patients with advanced NSCLC that was diagnosed via pathology or other imaging modalities, with no limitations of age, nationality, sex, or race.
2) Intervention: Experimental group treated with PD-1 or PD-L1 inhibitors alone (e.g., durvalumab, nivolumab, atezolizumab, pembrolizumab, or avelumab) irrespective of dosage and duration. The control groups were administered chemotherapy alone regardless of dosage and duration.
3) Outcome: The primary outcome was overall survival (OS) and secondary outcomes were progression-free survival (PFS) and the objective response rate (ORR).

Studies were excluded if complete test conditions were not available; if they were animal experimental research, reviews, and basic research or retrospective studies, other non-randomized controlled experiments, phase I and most low-quality II studies; if the experimental group was treated with PD-L1 inhibitor combined with other drugs; if the control group was not treated with chemotherapy alone; if consistent baseline levels of patients were missing; if intervention dosage was not completely clear, and if they were republished articles.

2.3. Risk of bias assessment

The Cochrane Risk of Bias Tool was used to evaluate the risk of bias.\(^{[8]}\) All included trials were assessed to have either high (green), unclear (yellow), or low (red) risk of bias based on the following 7 criteria:

1) random sequence generation,
2) allocation concealment,
3) blinding of participants and personnel,
4) blinding of outcome assessment,
5) incomplete outcome data,
6) selective reporting, and
7) other bias (Fig. 1).

Data extraction and quality assessment were performed independently by 3 authors. Any disagreements were resolved through discussion and consensus.

2.4. Data extraction

Three authors (LGJ Wu, DN Zhou, and JZ Ma) extracted data from 8 studies using a standardized data collection form. The reported hazard ratios (HRs) for OS and PFS and the related number of patients for the ORR were included. The following clinicopathological characteristics (Table 1) were recorded for each study: study name, trial phase, line of treatment, experimental drugs, assay developers for PD-L1 detection, observation, randomization stratified by pathology, and randomization stratified by PD-L1 expression. In addition, the inclusion and exclusion criteria, treatment received before the trial, protocol of the trial, and number of patients in each study were also recorded (Table 2).

2.5. Statistical analysis

The primary endpoint was OS and was defined as the time between diagnosis and death from any cause. It is the most recognized parameter for assessing the outcome of cancer
treatment. Similarly, the United States and European oncology groups agree that OS should be the primary outcome measure in clinical research. The PFS and ORR were the secondary outcomes.\textsuperscript{9–11}

Review Manager (RevMan; Version 5.3.5; The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, 2014), the Cochrane systematic review software, was used to systematically analyze outcomes of the 8 included studies and was used to conduct a subgroup analysis based on PD-1/PD-L1 expression (determined using TPS) and tumor pathology. The traditional method of processing time to event HRs uses the O-E/V data type to evaluate the HRs.\textsuperscript{12} The same generic inverse variance data could then be used by software conversion (for details on the hazard ratio of extraction and data conversion, refer to Supplemental S2, http://links.lww.com/MD/F949). Thus, we evaluated the hazards ratio (HR) and 95% confidence interval (CI) of OS, PFS, and ORR in each study.

We assessed the statistical heterogeneity between different trials and subgroups using the Cochrane’s $Q$ statistic. $I^2$ was calculated to assess the extent of inconsistency contributing to the heterogeneity across the different studies.\textsuperscript{13} The assumption of homogeneity was considered valid for $I^2 \leq 25\%$ and $P > .10$. In this study, a fixed-effects model was used when there was no obvious heterogeneity; otherwise, a random-effects model was used.

The Begg funnel plot was used to analyze publication bias, which was considered low when the completeness and symmetry of the Begg funnel plot were high.

3. Results

3.1. Literature search

A total of 2049 articles were identified by the original search strategy, among which 269 articles were removed because of
duplications and 187 were removed by adding qualifiers. After screening the titles and abstracts, 1474 papers were excluded; we then carefully reviewed the remaining 119 papers to shortlist 8 RCTs \(^{14–21}\) (Fig. 2) that met the inclusion criteria.

### 3.2. Study characteristics

A total of 4122 subjects were enrolled in the 8 studies, including 1979 in the experimental group and 2143 in the control group. The main features of the 8 studies are described in Table 1; these studies were either phase III or high quality multi-centered phase II clinical trials. All intervention groups received PD-L1 inhibitor treatment, with those in 3, 3, 1, and 1 studies receiving atezolizumab, \(^{14,19,21}\) nivolumab, \(^{15,16,20}\) avelumab, \(^{17}\) and pembrolizumab \(^{18}\) respectively. In all studies, PD-L1 inhibitors were used as second-line or later-line treatment. Apart from the study by Brahmer \(^{16}\) (Fig. 3B), PD-1 or PD-L1 inhibitors had the same effect on PFS as on OS (HR 0.87, 95%CI 0.78–0.97, \(P=.01\)). However, some statistical heterogeneity was observed (\(P=.06, I^2=46\)). By exploring sources of heterogeneity, we noted that the statistical heterogeneity disappeared after the removal of the study by Brahmer \(^{16}\) (\(P=.32, I^2=15\%\)) (Fig. 4A).

Similarly, statistical analysis also showed significant improvement in ORR in the treatment group than in the control group (HR 2.08, 95%CI 1.49–2.88, \(P<.001\)) (Fig. 3C). However, heterogeneity test results showed no obvious homogeneity (\(P=.03, I^2=52\%\)). By removing the study by Hida \(^{19}\) ORR heterogeneity disappeared (\(P=.43, I^2=0\%\)) (Fig. 4B). Thus, it is possible that its heterogeneity was due to the small sample size, resulting in a large effect from random errors.

### 3.4. Subgroup analysis

To explore the causes of heterogeneity, heterogeneity tests were conducted based on patients TPS and pathological classification. These 2 variables were chosen as they showed the most evident differences in the included studies based on statistical analyses.

### 3.5. PD-L1 expression status

In subgroup analyses of TPS (Fig. 5), patients with PD-L1 expression (TPS ≥ 1%) had significantly improved OS following PD-L1 inhibitor treatment than following control treatment (HR 0.71, 95%CI 0.64–0.78, \(P<.001\)). Notably, for patients without PD-L1 expression, PD-L1 inhibitors could still effectively reduce the risk of mortality (HR 0.75, 95%CI 0.63–0.89, \(P=.001\)).

---

**Table 1**

| Study                        | Year | Trial phase | Line of treatment | Clinical stage | Experimental drugs | Assay developer | Observation | Randomization stratified by pathology | Randomization stratified by PD-L1 expression |
|------------------------------|------|-------------|-------------------|----------------|-------------------|-----------------|------------|-------------------------------------|---------------------------------------------|
| Rittmeyer et al \(^{22}\)   | 2017 | III         | 2nd or later      | II/III          | Atezolizumab vs docetaxel | DN, Zhou       | OS         | PFS                                | NO                                          |
| Brahmer et al \(^{14}\)     | 2015 | III         | 2nd or later      | II/III          | Nivolumab vs docetaxel | JZ, Ma         | NO         | ORR                                | YES                                         |
| Borghaei et al \(^{21}\)   | 2019 | III         | 2nd or later      | IIIB or IV      | Nivolumab vs docetaxel | LGJ, Wu        | NO         | ORR                                | NO                                          |
| Barlesi et al \(^{14}\)     | 2018 | III         | 2nd or later      | IIIB or IV      | Avelumab vs docetaxel | JZ, Ma         | YES        | ORR                                | YES                                         |
| Herbst et al \(^{16}\)      | 2016 | III/II      | 2nd or later      | IIIB or IV      | Pembrolizumab vs docetaxel | LGJ, Wu        | YES        | ORR                                | YES                                         |
| Hida et al \(^{15}\)        | 2018 | III         | 2nd or later      | NR              | Atezolizumab vs docetaxel | LGJ, Wu        | NO         | ORR                                | YES                                         |
| Wu et al \(^{22}\)          | 2019 | III         | 2nd or later      | IIIB or IV      | Nivolumab vs docetaxel | DN, Zhou       | YES        | ORR                                | YES                                         |
| Fehrenbacher et al \(^{17}\)| 2016 | II          | 2nd or later      | NR              | Atezolizumab vs docetaxel | DN, Zhou       | YES        | ORR                                | YES                                         |

**Note:** NR = not reported, ORR = objective response rate, OS = overall survival, PFS = progression-free survival.
| Study            | Year | Inclusion criteria for patient selection                                                                 | Exclusion criteria for patient selection                                                                 | Previous treatment                                      | Treatment                                                                 | No. of patients |
|------------------|------|-------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------------------------|-----------------|
| Rittmeyer et al. | 2017 | Stage IIB or IV squamous cell or non-squamous cell NSCLC, measurable disease after prior chemotherapy.     | Autoimmune disease; prior therapy with checkpoint-targeted agents; prior docetaxel therapy.               | One to two previous cytotoxic chemotherapy regimens      | Atezolizumab (1200 mg q3w) or docetaxel (75 mg/m² q3w)                  | 850 (425/425)  |
|                  |      |                                                                                                             |                                                                                                          |                                                          |                                                                            |                 |
| Brahmer et al.   | 2015 | Stage IIB or IV squamous cell NSCLC with treated stable brain metastases; ECOG PS of 0 or 1; Age ≥ 18.    | Autoimmune disease; symptomatic interstitial lung disease; systemic immunosuppression; prior therapy with  | One prior platinum containing regimen                   | Nivolumab (3 mg/kg q2w) or docetaxel (75 mg/m² q3w)                     | 272 (135/137)  |
|                  |      |                                                                                                             | T-cell costimulation or checkpoint-targeted agents; prior docetaxel therapy.                            |                                                          |                                                                            |                 |
| Borghaei et al.  | 2015 | Stage IIB or IV recurrent non-squamous NSCLC, after radiation therapy or surgical resection and had also had | Autoimmune disease; symptomatic interstitial lung disease; systemic immunosuppression; prior treatment   | One prior platinum-based doublet chemotherapy regimen   | Nivolumab (3 mg/kg q2w) or docetaxel (75 mg/m² q3w)                     | 582 (292/290)  |
|                  |      | disease recurrence or progression; adequate hematologic, hepatic, and renal function; ECOG PS of 0 or 1; Age ≥ 18. | with immune-omulatory antitumor agents; prior docetaxel therapy.                                        |                                                          |                                                                            |                 |
| Bartlesi et al.  | 2018 | Stage IIB or IV recurrent NSCLC; disease progression after treatment with a platinum-containing doublet;   | Brain metastases; non-squamous cell NSCLC harboring an EGFR or ALK mutation; persisting toxicity after    | One prior platinum-based doublet chemotherapy regimen   | Avelumab (10 mg/kg q2w) or docetaxel (75 mg/m² q3w)                     | 529 (264/265)  |
|                  |      | adequate hematologic, renal, and hepatic function; ECOG PS of 0 or 1; Age ≥ 18.                              | previous treatment, or other clinically significant diseases.                                            |                                                          |                                                                            |                 |
| Herbst et al.    | 2016 | Stage IIB or IV NSCLC with progression as per RECIST v1.1 after 2 or more cycles of platinum-doublet        | Autoimmune disease; brain metastases; carcinomatous meningitis; interstitial lung disease or history of   | Two or more prior cycles of platinum-doublet chemotherapy | Pembrolizumab (2 mg/kg q3w) or pembrolizumab (10 mg/kg q3w) or           | 1034 (345/346/343)Δ |
|                  |      | chemotherapy; PD-L1 TPS ≥ 1%; aged ≥ 18; ECOG PS of 0 or 1.                                                | pneumonitis; prior treatment with PD-1 checkpoint inhibitors or docetaxel.                               |                                                          | docetaxel (75 mg/m² q3w)                                                |                 |
| Hida et al.      | 2018 | Squamous or non-squamous cell locally advanced or metastatic NSCLC, disease progression or after a platinum- | Autoimmune disease; had received prior therapy with docetaxel, CD137 agonists, antifibrotic T lymphocyte-  | One or two prior platinum-based chemotherapy             | Atezolizumab (1200 mg) or docetaxel (75 mg/m² q3w)                      | 64 (36/28)     |
|                  |      | based regimen; measurable disease per RECIST v1.1; tumor sample available for evaluation of PD-L1 expression; | associated antigen 4, or anti-PD-L1/PD-1 therapies.                                                    |                                                          |                                                                            |                 |
|                  |      | had received ≤ 2 prior chemotherapy regimens; aged ≥ 18; ECOG PS of 0 or 1.                                 |                                                                                                          |                                                          |                                                                            |                 |
| Wu et al.        | 2019 | Stage IIB or IV recurrent squamous or non-squamous cell NSCLC progressing or after 1 previous platinum-based | Active autoimmune disease, symptomatic interstitial lung disease, systemic immunosuppression, with       | One or more prior platinum containing regimen           | Nivolumab (3 mg/kg q2w) or docetaxel (75 mg/m² q3w)                     | 504 (338/166)  |
|                  |      | chemotherapy regimen; measurable disease per RECIST v1.1; aged ≥ 18; ECOG PS of 0 or 1.                    | EGFR-mutation-positive tumors or known ALK receptor tyrosine kinase (ALK) translocation-positive tumors; |                                                          |                                                                            |                 |
|                  |      |                                                                                                             | prior treatment with an EGFR, anaplastic lymphoma kinase inhibitor, antitumor vaccine, immuneostimulatory |                                                            |                                                                            |                 |
|                  |      |                                                                                                             | antitumor agent, immune checkpoint inhibitor, or docetaxel.                                            |                                                          |                                                                            |                 |
| Fehrenbacher et  | 2016 | Advanced or metastatic NSCLC; measurable disease per RECIST v1.1; adequate hematologic, end-organ function; | Active or untreated CNS metastases; history of pneumonitis, autoimmune or chronic viral diseases;      | One or more prior platinum containing regimen           | Atezolizumab (1200 mg) or docetaxel (75 mg/m² q3w)                      | 287 (144/143)  |
|                  |      | provided tumor specimens for central PD-L1 testing on formalin-fixed paraffin-embedded sections before     | previous treatment with docetaxel, CD137 agonists, anti-CTLA4, anti-PD-L1, or anti-PD-L1 therapeutic    |                                                          |                                                                            |                 |
|                  |      | enrollment; aged ≥ 18; ECOG PS of 0 or 1.                                                                   | antibodies, or PD-L1/PD-1 pathway-blocking agents.                                                      |                                                          |                                                                            |                 |

*Expressed as total number of patients (number of patients in intervention arm/number of patients in control arm). Δ The trial is divided into 3 groups (number of patients in intervention arm received pembrolizumab 2 mg/kg/number of patients in intervention arm received pembrolizumab 10 mg/kg/number of patients in control arm). CNS = central nervous system, ECOG = Eastern Cooperative Oncology Group, NSCLC = non-small-cell lung cancer, PS = performance status, RECIST = response evaluation criteria in solid tumors.
No substantial heterogeneity was observed between patients with PD-L1 expression ($P = .33$, $I^2 = 12\%$) and those without PD-L1 expression ($P = .60$, $I^2 = 0\%$) based on TPS analysis. Overall, this analysis showed a consistent baseline level of PD-L1 expression, as determined by TPS, for patients included in the literature and revealed that this variable was not associated with heterogeneity in the meta-analysis.

### 3.6. Tumor pathology

Subgroup analysis of tumor pathology revealed that compared with chemotherapy, PD-L1 inhibitors were effective in improving the OS of both advanced NSCLC patients with squamous cell carcinoma (HR 0.71, 95%CI 0.60–0.84, $P < .001$) and of those without squamous cell carcinoma (HR 0.76, 95%CI 0.68–0.86, $P < .001$) (Fig. 6).

Notably, statistical heterogeneity was found among the patients with non-squamous cell carcinoma ($P = .15$, $I^2 = 41\%$) but not among those with squamous cell carcinoma ($P = .92$, $I^2 = 0\%$).

In PFS analysis, the original apparent heterogeneity ($P = .06$, $I^2 = 46\%$) disappeared after excluding the study by Brahmer$^{[16]}$ ($P = .32$, $I^2 = 15\%$), which included only patients with squamous cell carcinoma. Thus, a lack of patients with non-squamous cell carcinoma led to heterogeneity in the subgroup analysis (Fig. 6). We believe that the classification of pathology was the main reason for the heterogeneity observed in PFS analysis.

### 3.7. Safety

A statistical analysis of 7 trials$^{[15–21]}$ using a forest plot (Fig. 7) to describe the number of patients with side effects showed that the
Figure 3. Hazard ratio of overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) for patients in intervention group compared with that in the control group. The effects of therapy were calculated using a fixed-effects model in A and using a random-effects model in B and C.
Figure 4. Hazard ratio of progression-free survival (PFS) and objective response rate (ORR) for patients in the intervention group compared with that in the control group after eliminating heterogeneity. The effects of the therapy were calculated using a fixed-effects model.

![Image of Figure 4](image)

**Table for Figure 4:**

| Study or Subgroup | log(Odds Ratio) | SE  | Weight | Odds Ratio IV, Fixed, 95% CI | Odds Ratio IV, Fixed, 95% CI |
|------------------|----------------|-----|--------|-------------------------------|-------------------------------|
| Barlesi,F 2018  | 0.01           | 0.12| 10.5%  | 1.01 (0.80, 1.28)             |                               |
| Borghaei,H 2015 | -0.08          | 0.092| 17.9%  | 0.92 (0.77, 1.11)             |                               |
| Brahmer,J 2015  | -0.48          | 0.14 | 0%     | 0.62 (0.47, 0.81)             |                               |
| Fehrenbacher,L 2016 | -0.06        | 0.139| 7.9%   | 0.94 (0.73, 1.23)             |                               |
| Herbst,RS(1) 2018 | -0.13        | 0.207| 3.5%   | 0.89 (0.59, 1.32)             |                               |
| Herbst,RS(2) 2016 | -0.24        | 0.092| 17.9%  | 0.79 (0.66, 0.94)             |                               |
| Hida,T 2018    | 0.31           | 0.268| 21.6%  | 1.36 (0.81, 2.21)             |                               |
| Rittmeyer,A 2017 | -0.05         | 0.074| 27.6%  | 0.95 (0.82, 1.10)             |                               |
| Wu,Y 2019     | -0.26          | 0.11 | 12.5%  | 0.77 (0.62, 0.96)             |                               |
| Total (95% CI) |                |     |        | 100.0%                        | 0.90 [0.83, 0.97]             |
| Heterogeneity: |                |     |        | Chi² = 8.20, df = 7 (P = 0.32); I² = 15% |                               |
| Test for overall effect: | Z = 2.71 (P = 0.007) |

Figure 5. Subgroup analysis for overall survival (OS) in PD-L1-positive/-negative patients determined using TPS in the intervention and control groups.

![Image of Figure 5](image)

**Table for Figure 5:**

| Study or Subgroup | Experimental Events | Total | Control Events | Total | Odds Ratio M.H. Fixed, 95% CI | Odds Ratio M.H. Fixed, 95% CI |
|------------------|---------------------|-------|----------------|-------|-------------------------------|-------------------------------|
| Barlesi,F 2018  | 50                  | 264   | 31             | 265   | 1.76 [1.09, 2.80]             |                               |
| Borghaei,H 2015 | 56                  | 292   | 36             | 260   | 1.87 [1.16, 2.94]             |                               |
| Brahmer,J 2015  | 27                  | 135   | 12             | 147   | 2.60 [1.26, 5.39]             |                               |
| Fehrenbacher,L 2016 | 12            | 21    | 5              | 26    | 4.27 [1.13, 16.05]            |                               |
| Herbst,RS(1) 2016 | 62               | 344   | 32             | 376   | 2.14 [1.35, 3.37]             |                               |
| Herbst,RS(2) 2016 | 64               | 346   | 32             | 378   | 2.21 [1.40, 3.47]             |                               |
| Hida,T 2018    | 4                  | 36    | 9              | 45    | 0.26 [0.07, 0.96]             |                               |
| Rittmeyer,A 2017 | 30               | 58    | 10             | 68    | 5.04 [2.14, 11.84]            |                               |
| Wu,Y 2019     | 37                  | 56    | 3              | 59    | 2.60 [1.53, 12.81]            |                               |
| Total (95% CI) | 1516               | 1463  | 100.0%         | 2.16 [1.75, 2.66] |
| Heterogeneity: | Chi² = 6.97, df = 7 (P = 0.42); I² = 0% |                               |
| Test for overall effect: | Z = 2.77 (P = 0.00001) |

Subgroup Analysis for OS (OS) in PD-L1-PD-L1-positive/-negative patients determined using TPS in the intervention and control groups.
Figure 6. Subgroup analysis for overall survival (OS) in patients with squamous or non-squamous carcinoma between the intervention and control groups.

| Study or Subgroup | log(Odds Ratio) | SE   | Weight | Odds Ratio (IV, Fixed), 95% CI |
|-------------------|----------------|------|--------|-----------------------------|
| 1.3.1 Squamous    |                |      |        |                             |
| Barlesi,F 2018    | -0.36          | 0.189| 6.8%   | 0.70 [0.48, 1.01]           |
| Fehrenbacher,L 2016 | -0.22          | 0.247| 4.0%   | 0.80 [0.49, 1.30]           |
| Herbst,RS 2016    | -0.3           | 0.199| 6.2%   | 0.74 [0.50, 1.09]           |
| Rittmeyer,A 2017  | -0.31          | 0.153| 10.4%  | 0.73 [0.54, 0.99]           |
| Wu,Y 2019         | -0.49          | 0.191| 6.7%   | 0.61 [0.42, 0.89]           |
| Subtotal (95% CI) |                |      |        |                             |
|                   | 34.1%          |      |        | 0.71 [0.60, 0.84]           |

Heterogeneity: $\chi^2 = 0.94, \text{df} = 4 \ (P = 0.92); I^2 = 0$
Test for overall effect: $Z = 4.05 \ (P < 0.0001)$

1.3.2 Non-squamous

| Study or Subgroup | log(Odds Ratio) | SE   | Weight | Odds Ratio (IV, Fixed), 95% CI |
|-------------------|----------------|------|--------|-----------------------------|
| Barlesi,F 2018    | 0.02           | 0.135| 13.4%  | 1.02 [0.78, 1.33]           |
| Fehrenbacher,L 2016 | -0.37          | 0.196| 6.3%   | 0.69 [0.47, 1.01]           |
| Herbst,RS 2016    | -0.46          | 0.145| 11.6%  | 0.63 [0.48, 0.84]           |
| Rittmeyer,A 2017  | -0.31          | 0.099| 24.9%  | 0.73 [0.60, 0.89]           |
| Wu,Y 2019         | -0.27          | 0.158| 9.8%   | 0.76 [0.56, 1.04]           |
| Subtotal (95% CI) |                |      |        |                             |
|                   | 65.9%          |      |        | 0.76 [0.68, 0.86]           |

Heterogeneity: $\chi^2 = 6.75, \text{df} = 4 \ (P = 0.15); I^2 = 41$
Test for overall effect: $Z = 4.43 \ (P < 0.00001)$
Test for subarous differences: $\chi^2 = 0.50, \text{df} = 1 \ (P = 0.48); I^2 = 0$

Total (95% CI) 100.0% 0.74 [0.68, 0.82]

Heterogeneity: $\chi^2 = 8.20, \text{df} = 9 \ (P = 0.51); I^2 = 0$
Test for overall effect: $Z = 5.96 \ (P < 0.00001)$
Test for subarous differences: $\chi^2 = 0.50, \text{df} = 1 \ (P = 0.48); I^2 = 0$

Figure 7. Hazard ratios of any grade adverse events (AEs)/grades 3–5 AEs for patients in the intervention and control groups. The effect of the therapy was calculated using a random-effects model.
number of any grade side effects in the experimental group was significantly lower than that in the control group (HR 0.34, 95% CI 0.29–0.39, P < .001). Moreover, no heterogeneity was observed between the groups in this regard (P = .44; I² = 0%).

The number of grade ≥3 side effects in the experimental group was also significantly lower than that in the control group (HR 0.15, 95% CI 0.10–0.23, P < .001). However, as assessed by random-effects model, there was still obvious heterogeneity (P < .001; I² = 84%). This heterogeneity possibly observed because 2 of the 7 trials[17,18] reported grades 3 to 5 side effects, whereas the other 5 RCTs reported only the number of patients with grades 3 to 4 side effects.

3.8. Publication bias analysis

A visual inspection of the Begg funnel plot showed some asymmetry (Fig. 8). All 8 trials were at the left side of the line (OR = 1), indicating that there may be publication bias.

4. Discussion

At present, many clinical trials have shown that for treating patients with advanced NSCLC, pembrolizumab in combination with chemotherapy, as a first-line treatment, has a significantly better curative effect than chemotherapy alone.[22–26] However, another study has shown that PD-L1 inhibitors, such as nivolumab, combined with chemotherapy, when used as the first-line treatment for NSCLC, have a high rate of discontinuation owing to treatment-related adverse events (approximately 21%). The adverse events resulting from the combined use of PD-L1 inhibitors and platinum-based doublet chemotherapy cannot be ignored.[5] Notably, in recent years, platinum chemotherapy has been used as the first-line therapy for advanced NSCLC patients without target-driven gene mutations,[27] but the problem of the high incidence of adverse reactions is difficult to address.[28] PD-L1 inhibitors when used in combination chemotherapy result in serious side effects and high drug withdrawal rate. In addition, a report has demonstrated that the incidence of grades 3 and 4 immune-related adverse events following immunosuppressant treatment is higher than that reported in clinical trials.[6] Currently, it is critical to understand whether immunosuppressant drugs can prevent serious adverse events caused by chemotherapy when they are used alone as second- or later-line treatment and to ensure that they still have a good curative effect and are safe for patients.

This meta-analysis is to investigate and analyze the latest RCT evidence regarding the efficacy and safety of PD-L1 inhibitors alone with those of chemotherapy for treating advanced NSCLC. During the article screening process, some of the excluded literature was of high quality and highly consistent with screening criteria, but they allowed chemotherapy arm patients to receive immunotherapy in the event of disease progression.[29] Although the complexity of clinical trials is taken into account, the researchers have to loosen test standards in some cases. However, in strict accordance with the statistical analysis, we believe that even if the patients meet the safety standards, the progress of the disease should be counted as the number of outcome indicators in the current treatment group, and should not receive immune checkpoint blockade treatment. This will lead to a large degree of deviation on the overall results. Through the analysis of the final 8 high-quality RCTs, enrolling more than 4000 patients with advanced NSCLC, we revealed that PD-L1 inhibitors, when used alone as second-line or later-line treatment, can effectively improve the OS and PFS compared with chemotherapy. Moreover, we noted that the ORR was also better following PD-L1 treatment than following chemotherapy. Furthermore, as determined using TPS, both PD-L1-positive and -negative patients benefit more from PD-L1 inhibitors than from traditional chemotherapy. Similarly, the efficacy of PD-L1 inhibitors in patients with squamous cell carcinoma and those with non-squamous cell carcinoma is also better than that of chemotherapy. However, our analyses failed to demonstrate if
the tumor pathology and TPS score of tumors can be used as indicators of treatment selection for advanced NSCLC. Regarding safety, PD-L1 inhibitor treatment was associated with significantly fewer adverse effects than chemotherapy.

Irrespective, this study has some limitations. First, although all 8 trials were found to have a low risk of bias regarding blinding of participants, no studies used the blinding method during intervention. This is because of the inevitability of not being able to follow blinding when performing a subgroup analysis for assessing the effect of TPS and tumor pathology on the efficacy of PD-L1 inhibitors. In addition, randomly grouping patients according to TPS or tumor pathology will result in new intergroup differences, leading to a patients inconsistent baseline level of the study, which will affect the results. Second, most studies included in this meta-analysis enrolled European and American patients, and only 2 studies enrolled Asian patients,[19,21] which may have led to a racial bias. Therefore, the results can only be generalized to European and American patients. Third, the assessment of publication bias was not convincing enough owing to the inclusion of only few articles. Therefore, further studies using more large-scale and high-quality RCTs are needed.

This meta-analysis aimed to conduct a comprehensive and strict search of clinical trials that met appropriate standards. It showed that PD-L1 inhibitors possess significant efficacy and safety as a second-line and later-line therapies for patients with advanced NSCLC. For patients with poor health status caused by advanced disease or first-line treatment-related side effects, PD-L1 inhibitors alone can effectively reduce the risk of mortality and improve the quality of life without the requirement for chemotherapy, which causes considerable toxicity and adverse effects. We believe that the results of this meta-analysis will help improve clinical treatment plans and provide new treatment options for patients with advanced NSCLC.

Author contributions

WD and HS developed the study concept. All authors contributed to the study design. LW, DZ, and JM participated in literature searching and data extraction. LW, JM, and TW conducted the data analysis. LW and DZ interpreted the results and drafted the paper under the supervision of WD and HS. All authors approved the final version of the paper for submission.

Conceptualization: Lin-guang-jin Wu, Hua Sui, Wan-li Deng.

Data curation: Lin-guang-jin Wu, Dan-ni Zhou, Jun-zhi Ma.

Formal analysis: Dan-ni Zhou, Ting Wang.

Investigation: Jun-zhi Ma.

Software: Dan-ni Zhou.

Validation: Wan-li Deng.

Visualization: Hua Sui, Wan-li Deng.

Writing – original draft: Lin-guang-jin Wu.

References

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
[2] Powell CA, Halmos B, Nana-Seeckam SP. Update in lung cancer and mesothelioma. 2012. Am J Respir Crit Care Med 2013;188:157–66.
[3] Dann M, Roese K, Jacob C. Health-related quality of life questionnaires in lung cancer trials: a systematic literature review. Health Econ Rev 2013;3:15.
[4] Xu-Monette ZY, Zhang M, Li J, et al. PD-L1/PD-L1 Blockade: have we found the key to unleash the antitumor immune response? Front Immunol 2017;8:1597.
[5] Ruvi NA, Hellmann MD, Brahmer JR, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2016;34:2969–79.
[6] Bjoernhart B, Hansen KH, Jorgensen TL, et al. Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study. Acta Oncol 2019;58:593–61.
[7] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62:e1–34.
[8] Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
[9] Noonan AM, Bekaii-Saab T. Second-line outcomes in metastatic colorectal cancer – raising the bar for the high jump rather than the doing the limbo. Expert Rev Pharmacoecon Outcomes Res 2015;15:133–43.
[10] Wild C, Grossmann N, Bonanno PV, et al. Utilisation of the ESMO-MCBS in practice of HTA. Ann Oncol 2016;27:134–6.
[11] Ellis LM, Bernstein DS, Voest EE, et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol 2014;32:1277–80.
[12] Tierney JF, Stewart LA, Gherzi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
[13] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:567–70.
[14] Barlesi F, Vansteenkiste J, Spigel D, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol 2018;19:1468–79.
[15] Borghei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627–39.
[16] Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-Cell non-small-cell lung cancer. N Engl J Med 2015;373:125–35.
[17] Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837–46.
[18] Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540–50.
[19] Hida T, Kaji R, Satouchi M, et al. Atezolizumab in Japanese patients with previously treated advanced non-small-cell lung cancer: a subgroup analysis of the phase 3 OAK Study. Clin Lung Cancer 2018;19:e405–15.
[20] Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255–65.
[21] Wu YL, Lu S, Cheng Y, et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial. J Thorac Oncol 2019;14:867–75.
[22] Pai-Scherf L, Blumenthal GM, Li HS, et al. FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond. Oncologist 2017;22:1392–9.
[23] Hui R, Garon EB, Goldman JW, et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol 2017;28:874–81.
[24] Borgenhi H, Langer CJ, Gadgeel S, et al. 24-Month overall survival from KEYNOTE-021 cohort G: pembrolizumab and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol 2019;14:124–9.
[25] Gandhi L, Rodríguez-Abreú D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018;378:2078–92.
[26] Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 2018;379:2040–51.

[27] Hsu WH, Yang JC, Mok TS, et al. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol 2018;29(Suppl_1):i3–9.

[28] Liang HR, Liu ZC, Cai XY, et al. PD-(L)1 inhibitors vs. chemotherapy vs. their combination in front-line treatment for NSCLC: an indirect comparison. Int J Cancer 2019;145:3011–21.

[29] Reck M, Rodriguez-Abreu D, Robinson AG, et al. KEYNOTE-024 InvestigatorsPembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823–33.